Package | us.nlm.vsac |
Resource Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1234.75 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1234.75/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75 |
Version | 20220106 |
Status | active |
Date | 2022-01-06T01:02:20-05:00 |
Name | COVID19VaccineICD10PCSCodesForExposureIdentification |
Title | COVID19 vaccine ICD10PCS codes for exposure identification |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: COVID-19 vaccine ICD10PCS codes for identification of potential biologics-related adverse events.),(Data Element Scope: This value set may use a model element in the QDM category of Procedure/Intervention, Immunization, Medication, or Substance.),(Inclusion Criteria: COVID-19 vaccine ICD10PCS codes.),(Exclusion Criteria: None) |
No resources found
CodeSystem | |
ICD10 | ICD-10 Procedure Codes |
No narrative content found in resource
{ "resourceType": "ValueSet", "id": "2.16.840.1.113762.1.4.1234.75", "meta": { "versionId": "6", "lastUpdated": "2023-12-21T17:43:03.000-05:00", "profile": [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ] }, "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/valueset-author", "valueContactDetail": { "name": "BEST System Author" } }, { "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate", "valueDate": "2024-04-04" }, { "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate", "valueDate": "2022-01-06" } ], "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75", "identifier": [ { "system": "urn:ietf:rfc:3986", "value": "urn:oid:2.16.840.1.113762.1.4.1234.75" } ], "version": "20220106", "name": "COVID19VaccineICD10PCSCodesForExposureIdentification", "title": "COVID19 vaccine ICD10PCS codes for exposure identification", "status": "active", "experimental": false, "date": "2022-01-06T01:02:20-05:00", "publisher": "BEST System Steward", "jurisdiction": [ { "coding": [ { "system": "urn:iso:std:iso:3166", "code": "US" } ] } ], "purpose": "(Clinical Focus: COVID-19 vaccine ICD10PCS codes for identification of potential biologics-related adverse events.),(Data Element Scope: This value set may use a model element in the QDM category of Procedure/Intervention, Immunization, Medication, or Substance.),(Inclusion Criteria: COVID-19 vaccine ICD10PCS codes.),(Exclusion Criteria: None)", "compose": { "include": [ { "system": "http://www.cms.gov/Medicare/Coding/ICD10", "concept": [ { "code": "XW013S6", "display": "Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6" }, { "code": "XW013T6", "display": "Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6" }, { "code": "XW013U6", "display": "Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6" }, { "code": "XW023S6", "display": "Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6" }, { "code": "XW023T6", "display": "Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6" }, { "code": "XW023U6", "display": "Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6" } ] } ] }, "expansion": { "identifier": "urn:uuid:33f17690-c72b-4014-bc35-dc775e2d4e30", "timestamp": "2025-05-23T20:15:25-04:00", "total": 6, "contains": [ { "system": "http://www.cms.gov/Medicare/Coding/ICD10", "version": "2025", "code": "XW013S6", "display": "Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6" }, { "system": "http://www.cms.gov/Medicare/Coding/ICD10", "version": "2025", "code": "XW013T6", "display": "Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6" }, { "system": "http://www.cms.gov/Medicare/Coding/ICD10", "version": "2025", "code": "XW013U6", "display": "Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6" }, { "system": "http://www.cms.gov/Medicare/Coding/ICD10", "version": "2025", "code": "XW023S6", "display": "Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6" }, { "system": "http://www.cms.gov/Medicare/Coding/ICD10", "version": "2025", "code": "XW023T6", "display": "Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6" }, { "system": "http://www.cms.gov/Medicare/Coding/ICD10", "version": "2025", "code": "XW023U6", "display": "Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6" } ] } }